150 related articles for article (PubMed ID: 35118587)
21. Up-regulation of NMRK2 mediated by TFE3 fusions is the key for energy metabolism adaption of Xp11.2 translocation renal cell carcinoma.
Chen Y; Yang L; Lu Y; Liu N; Ma W; Fan H; Hu Q; Han X; Gan W; Li D
Cancer Lett; 2022 Jul; 538():215689. PubMed ID: 35447281
[TBL] [Abstract][Full Text] [Related]
22. Molecular-genetic analysis is essential for accurate classification of renal carcinoma resembling Xp11.2 translocation carcinoma.
Hayes M; Peckova K; Martinek P; Hora M; Kalusova K; Straka L; Daum O; Kokoskova B; Rotterova P; Pivovarčikova K; Branzovsky J; Dubova M; Vesela P; Michal M; Hes O
Virchows Arch; 2015 Mar; 466(3):313-22. PubMed ID: 25544614
[TBL] [Abstract][Full Text] [Related]
23. Diagnosis of uncommon renal epithelial neoplasms: performances of fluorescence in situ hybridization.
Beaumont M; Dugay F; Kammerer-Jacquet SF; Jaillard S; Cabillic F; Mathieu R; Verhoest G; Bensalah K; Rioux-Leclercq N; Belaud-Rotureau MA;
Hum Pathol; 2019 Oct; 92():81-90. PubMed ID: 31437522
[TBL] [Abstract][Full Text] [Related]
24. Identification by FFPE RNA-Seq of a new recurrent inversion leading to RBM10-TFE3 fusion in renal cell carcinoma with subtle TFE3 break-apart FISH pattern.
Just PA; Letourneur F; Pouliquen C; Dome F; Audebourg A; Biquet P; Vidaud M; Terris B; Sibony M; Pasmant E
Genes Chromosomes Cancer; 2016 Jun; 55(6):541-8. PubMed ID: 26998913
[TBL] [Abstract][Full Text] [Related]
25. TFE3 Xp11.2 Translocation Renal Cell Carcinoma Mouse Model Reveals Novel Therapeutic Targets and Identifies GPNMB as a Diagnostic Marker for Human Disease.
Baba M; Furuya M; Motoshima T; Lang M; Funasaki S; Ma W; Sun HW; Hasumi H; Huang Y; Kato I; Kadomatsu T; Satou Y; Morris N; Karim BO; Ileva L; Kalen JD; Wilan Krisna LA; Hasumi Y; Sugiyama A; Kurahashi R; Nishimoto K; Oyama M; Nagashima Y; Kuroda N; Araki K; Eto M; Yao M; Kamba T; Suda T; Oike Y; Schmidt LS; Linehan WM
Mol Cancer Res; 2019 Aug; 17(8):1613-1626. PubMed ID: 31043488
[TBL] [Abstract][Full Text] [Related]
26. Targeting chemoresistance in Xp11.2 translocation renal cell carcinoma using a novel polyamide-chlorambucil conjugate.
Funasaki S; Mehanna S; Ma W; Nishizawa H; Kamikubo Y; Sugiyama H; Ikeda S; Motoshima T; Hasumi H; Linehan WM; Schmidt LS; Ricketts C; Suda T; Oike Y; Kamba T; Baba M
Cancer Sci; 2022 Jul; 113(7):2352-2367. PubMed ID: 35396773
[TBL] [Abstract][Full Text] [Related]
27. The suitability of NONO-TFE3 dual-fusion FISH assay as a diagnostic tool for NONO-TFE3 renal cell carcinoma.
Liu N; Guo W; Shi Q; Zhuang W; Pu X; Chen S; Qu F; Xu L; Zhao X; Li X; Zhang G; Guo H; Gan W; Li D
Sci Rep; 2020 Oct; 10(1):16361. PubMed ID: 33004995
[TBL] [Abstract][Full Text] [Related]
28. Chameleon TFE3-translocation RCC and How Gene Partners Can Change Morphology: Accurate Diagnosis Using Contemporary Modalities.
Tretiakova MS
Adv Anat Pathol; 2022 May; 29(3):131-140. PubMed ID: 35180736
[TBL] [Abstract][Full Text] [Related]
29. Novel gene fusion of PRCC-MITF defines a new member of MiT family translocation renal cell carcinoma: clinicopathological analysis and detection of the gene fusion by RNA sequencing and FISH.
Xia QY; Wang XT; Ye SB; Wang X; Li R; Shi SS; Fang R; Zhang RS; Ma HH; Lu ZF; Shen Q; Bao W; Zhou XJ; Rao Q
Histopathology; 2018 Apr; 72(5):786-794. PubMed ID: 29148086
[TBL] [Abstract][Full Text] [Related]
30. Usefulness of a break-apart FISH assay in the diagnosis of Xp11.2 translocation renal cell carcinoma.
Kim SH; Choi Y; Jeong HY; Lee K; Chae JY; Moon KC
Virchows Arch; 2011 Sep; 459(3):299-306. PubMed ID: 21773754
[TBL] [Abstract][Full Text] [Related]
31. TFE3 translocation and protein expression in renal cell carcinoma are correlated with poor prognosis.
Lee HJ; Shin DH; Kim SY; Hwang CS; Lee JH; Park WY; Choi KU; Kim JY; Lee CH; Sol MY; Rha SH; Park SW
Histopathology; 2018 Nov; 73(5):758-766. PubMed ID: 29968390
[TBL] [Abstract][Full Text] [Related]
32. Renal Cell Carcinoma Associated with Xp11.2 Translocation/TFE3 Gene Fusions: Clinical Features, Treatments and Prognosis.
Liu N; Wang Z; Gan W; Xiong L; Miao B; Chen X; Guo H; Li D
PLoS One; 2016; 11(11):e0166897. PubMed ID: 27893792
[TBL] [Abstract][Full Text] [Related]
33. Integrative clinical and molecular characterization of translocation renal cell carcinoma.
Bakouny Z; Sadagopan A; Ravi P; Metaferia NY; Li J; AbuHammad S; Tang S; Denize T; Garner ER; Gao X; Braun DA; Hirsch L; Steinharter JA; Bouchard G; Walton E; West D; Labaki C; Dudani S; Gan CL; Sethunath V; Carvalho FLF; Imamovic A; Ricker C; Vokes NI; Nyman J; Berchuck JE; Park J; Hirsch MS; Haq R; Mary Lee GS; McGregor BA; Chang SL; Feldman AS; Wu CJ; McDermott DF; Heng DYC; Signoretti S; Van Allen EM; Choueiri TK; Viswanathan SR
Cell Rep; 2022 Jan; 38(1):110190. PubMed ID: 34986355
[TBL] [Abstract][Full Text] [Related]
34. TFE3 break-apart FISH has a higher sensitivity for Xp11.2 translocation-associated renal cell carcinoma compared with TFE3 or cathepsin K immunohistochemical staining alone: expanding the morphologic spectrum.
Rao Q; Williamson SR; Zhang S; Eble JN; Grignon DJ; Wang M; Zhou XJ; Huang W; Tan PH; Maclennan GT; Cheng L
Am J Surg Pathol; 2013 Jun; 37(6):804-15. PubMed ID: 23598965
[TBL] [Abstract][Full Text] [Related]
35. PRCC, the commonest TFE3 fusion partner in papillary renal carcinoma is associated with pre-mRNA splicing factors.
Skalsky YM; Ajuh PM; Parker C; Lamond AI; Goodwin G; Cooper CS
Oncogene; 2001 Jan; 20(2):178-87. PubMed ID: 11313942
[TBL] [Abstract][Full Text] [Related]
36. Contrast-enhanced ultrasound findings of adult renal cell carcinoma associated with Xp11.2 translocation/TFE3 gene fusion: comparison with clear cell renal cell carcinoma and papillary renal cell carcinoma.
Wei S; Tian F; Xia Q; Huang P; Zhang Y; Xia Z; Wu M; Yang B
Cancer Imaging; 2019 Dec; 20(1):1. PubMed ID: 31892340
[TBL] [Abstract][Full Text] [Related]
37. RBM10-TFE3 fusions: A FISH-concealed anomaly in adult renal cell carcinomas displaying a variety of morphological and genomic features: Comprehensive study of six novel cases.
Di Mauro I; Dadone-Montaudie B; Sibony M; Ambrosetti D; Molinie V; Decaussin-Petrucci M; Bland V; Arbaud C; Cenciu B; Arbib F; Just PA; Derman J; Rioux-Leclercq N; Pedeutour F;
Genes Chromosomes Cancer; 2021 Nov; 60(11):772-784. PubMed ID: 34358382
[TBL] [Abstract][Full Text] [Related]
38. Integrated exome and RNA sequencing of TFE3-translocation renal cell carcinoma.
Sun G; Chen J; Liang J; Yin X; Zhang M; Yao J; He N; Armstrong CM; Zheng L; Zhang X; Zhu S; Sun X; Yang X; Zhao W; Liao B; Pan X; Nie L; Yang L; Chen Y; Zhao J; Zhang H; Dai J; Shen Y; Liu J; Huang R; Liu J; Wang Z; Ni Y; Wei Q; Li X; Zhou Q; Huang H; Liu Z; Shen P; Chen N; Zeng H
Nat Commun; 2021 Sep; 12(1):5262. PubMed ID: 34489456
[TBL] [Abstract][Full Text] [Related]
39. Preoperative neutrophil-to-lymphocyte ratio predicts the surgical outcome of Xp11.2 translocation/TFE3 renal cell carcinoma patients.
Agizamhan S; Qu F; Liu N; Sun J; Xu W; Zhang L; Guo H; Gan W
BMC Urol; 2018 Jun; 18(1):60. PubMed ID: 29890986
[TBL] [Abstract][Full Text] [Related]
40. CircMET promotes tumor proliferation by enhancing CDKN2A mRNA decay and upregulating SMAD3.
Yang L; Chen Y; Liu N; Lu Y; Ma W; Yang Z; Gan W; Li D
Mol Cancer; 2022 Jan; 21(1):23. PubMed ID: 35042525
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
